{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:52:33Z","timestamp":1769025153448,"version":"3.49.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beem.2010.11.003","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T16:25:31Z","timestamp":1308500731000},"page":"501-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity"],"prefix":"10.1016","volume":"25","author":[{"given":"Aoife G.","family":"Cotter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Powderly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.beem.2010.11.003_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283365356","article-title":"Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV","volume":"24","author":"Neuhaus","year":"2010","journal-title":"AIDS"},{"issue":"3 Pt 2","key":"10.1016\/j.beem.2010.11.003_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0002-9343(88)90144-1","article-title":"Endocrine disorders in men infected with human immunodeficiency virus","volume":"84","author":"Dobs","year":"1988","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.beem.2010.11.003_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/j.1743-6109.2010.01886.x","article-title":"The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected males","author":"Moreno-Perez","year":"2010","journal-title":"Journal of Sexual Medicine"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/apc.2006.0071","article-title":"Erectile dysfunction and hypogonadism among men with HIV","volume":"21","author":"Crum-Cianflone","year":"2007","journal-title":"AIDS Patient Care and STDS"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1086\/317457","article-title":"Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy","volume":"31","author":"Rietschel","year":"2000","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1016\/j.beem.2010.11.003_bib7","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/498311","article-title":"Androgen levels in older men who have or who are at risk of acquiring HIV infection","volume":"41","author":"Klein","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0090-4295(87)90118-X","article-title":"Histopathology of testis in acquired immune deficiency syndrome","volume":"29","author":"Chabon","year":"1987","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0046-8177(89)90246-3","article-title":"Testicular atrophy in homosexual AIDS patients: an immune-mediated phenomenon?","volume":"20","author":"De Paepe","year":"1989","journal-title":"Human Pathology"},{"issue":"1\u20132","key":"10.1016\/j.beem.2010.11.003_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-0378(98)00049-7","article-title":"HIV in testis: quantitative histology and HIV localization in germ cells","volume":"41","author":"Shevchuk","year":"1998","journal-title":"Journal of Reproductive Immunology"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(98)00463-4","article-title":"Changing testicular histology in AIDS: its implication for sexual transmission of HIV","volume":"53","author":"Shevchuk","year":"1999","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib12","first-page":"518","article-title":"Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome","volume":"17","author":"Sellmeyer","year":"1996","journal-title":"Endocrine Reviews"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00042560-199712010-00006","article-title":"Testosterone replacement treatment options for HIV-infected men","volume":"16","author":"Cofrancesco","year":"1997","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1210\/jcem-65-3-482","article-title":"Adrenocortical function in acquired immunodeficiency syndrome","volume":"65","author":"Membreno","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1016\/j.beem.2010.11.003_bib15","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1210\/jcem.86.9.7843","article-title":"Mechanisms of androgen deficiency in human immunodeficiency virus-infected women with the wasting syndrome","volume":"86","author":"Grinspoon","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"14","key":"10.1016\/j.beem.2010.11.003_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.1988.03720140043031","article-title":"The relationship of gonadal activity and chemotherapy-induced gonadal damage","volume":"259","author":"Rivkees","year":"1988","journal-title":"JAMA"},{"issue":"8960","key":"10.1016\/j.beem.2010.11.003_bib17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(95)90950-8","article-title":"Reversible hypopituitarism after interferonalfa therapy","volume":"345","author":"Sakane","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00042560-199502000-00013","article-title":"Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness","volume":"8","author":"Wagner","year":"1995","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2010.11.003_bib19","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1086\/375879","article-title":"Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease","volume":"37","author":"Cooper","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1016\/j.beem.2010.11.003_bib20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/meta.2000.8625","article-title":"Validation of a screening questionnaire for androgen deficiency in aging males","volume":"49","author":"Morley","year":"2000","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/BF03344932","article-title":"Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients","volume":"15","author":"Martin","year":"1992","journal-title":"Journal of Endocrinological Investigation"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1310\/hct0806-412","article-title":"Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men","volume":"8","author":"Scott","year":"2007","journal-title":"HIV Clinical Trials"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0002-9343(99)00193-X","article-title":"The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection","volume":"107","author":"Dobs","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"9","key":"10.1016\/j.beem.2010.11.003_bib24","first-page":"3155","article-title":"Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels","volume":"83","author":"Bhasin","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/515162","article-title":"Sustained anabolic effects of long-term androgen administration in men with AIDS wasting","volume":"28","author":"Grinspoon","year":"1999","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.283.6.763","article-title":"Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels","volume":"283","author":"Bhasin","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib27","first-page":"60","article-title":"Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men","volume":"85","author":"Grinspoon","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archpsyc.57.2.141","article-title":"A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms","volume":"57","author":"Rabkin","year":"2000","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib29","first-page":"1332","article-title":"Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting","volume":"82","author":"Grinspoon","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1086\/322695","article-title":"Diagnosis and treatment of androgen deficiency in human immunodeficiency virus-infected men and women","volume":"33","author":"Mylonakis","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/QAD.0b013e3283299145","article-title":"Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial","volume":"23","author":"Dolan Looby","year":"2009","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00126334-200009010-00003","article-title":"Osteonecrosis in HIV: a case-control study","volume":"25","author":"Scribner","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib33","first-page":"160","article-title":"Avascular necrosis of the femoral head in HIV-infected patients","volume":"75","author":"Chevalier","year":"1993","journal-title":"The Journal of Bone and Joint Surgery. British Volume"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2214\/ajr.171.4.9762981","article-title":"Osteonecrosis of the knee in an HIV-infected patient","volume":"171","author":"Llauger","year":"1998","journal-title":"AJR American Journal of Roentgenology"},{"issue":"10","key":"10.1016\/j.beem.2010.11.003_bib35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/41.10.1200","article-title":"Multiple site osteonecrosis in HIV infection","volume":"41","author":"Mullan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.qai.0000225012.53568.20","article-title":"Osteonecrosis in patients infected with HIV: clinical epidemiology and natural history in a large case series from Spain","volume":"42","author":"Gutierrez","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib37","first-page":"451","article-title":"Avascular necrosis of the hip in a man with HIV infection","volume":"66","author":"Goorney","year":"1990","journal-title":"Genitourinary Medicine"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-137-1-200207020-00008","article-title":"High prevalence of osteonecrosis of the femoral head in HIV-infected adults","volume":"137","author":"Miller","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1086\/511683","article-title":"The incidence and natural history of osteonecrosis in HIV-infected adults","volume":"44","author":"Morse","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00002030-200202150-00021","article-title":"Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors","volume":"16","author":"Gutierrez","year":"2002","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S1413-86702007000100009","article-title":"Avascular necrosis of the femoral head in HIV infected patients","volume":"11","author":"Matos","year":"2007","journal-title":"The Brazilian Journal of Infectious Diseases"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib42","first-page":"1543","article-title":"Avascular necrosis and protease inhibitors","volume":"97","author":"Reddy","year":"2005","journal-title":"Journal of the National Medical Association"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/322779","article-title":"Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study","volume":"184","author":"Glesby","year":"2001","journal-title":"The Journal of Infectious Diseases"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib44","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1086\/428837","article-title":"Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997\u20132002, France","volume":"40","author":"Lawson-Ayayi","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1016\/j.beem.2010.11.003_bib45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.aids.0000238409.90571.02","article-title":"Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy","volume":"20","author":"Mary-Krause","year":"2006","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib46","first-page":"1","article-title":"Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management","volume":"17","author":"Allison","year":"2003","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/keh481","article-title":"Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study","volume":"44","author":"Agarwala","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib48","first-page":"1013","article-title":"The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years","volume":"91","author":"Agarwala","year":"2009","journal-title":"The Journal of Bone and Joint Surgery. British Volume"},{"key":"10.1016\/j.beem.2010.11.003_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.blo.0000194078.32776.31","article-title":"Does alendronate prevent collapse in osteonecrosis of the femoral head?","volume":"443","author":"Nishii","year":"2006","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","article-title":"Pre-existing fractures and bone mass predict vertebral fracture incidence in women","volume":"114","author":"Ross","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"issue":"9156","key":"10.1016\/j.beem.2010.11.003_bib53","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","article-title":"Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection","volume":"21","author":"Arnsten","year":"2007","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e3282f423dd","article-title":"Reduced bone mineral density in HIV-infected patients: prevalence and associated factors","volume":"22","author":"Cazanave","year":"2008","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002030-200402200-00014","article-title":"Reduced bone density in HIV-infected women","volume":"18","author":"Dolan","year":"2004","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib57","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/QAD.0b013e32832c4947","article-title":"First line zidovudine\/lamivudine\/lopinavir\/ritonavir leads to greater bone loss compared to nevirapine\/lopinavir\/ritonavir","volume":"23","author":"van Vonderen","year":"2009","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.beem.2010.11.003_bib58","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","article-title":"Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients","volume":"23","author":"Duvivier","year":"2009","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","article-title":"Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals","volume":"36","author":"Mondy","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1359\/JBMR.0301246","article-title":"BMD is reduced in HIV-infected men irrespective of treatment","volume":"19","author":"Amiel","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib61","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00002030-200104130-00005","article-title":"Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00002030-200104130-00022","article-title":"Osteopenia in HIV-infected patients: is it the disease or is it the treatment?","volume":"15","author":"Knobel","year":"2001","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib63","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00198-005-1845-0","article-title":"Bone mass and mineral metabolism in HIV+ postmenopausal women","volume":"16","author":"Yin","year":"2005","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e328334fe9a","article-title":"HIV and bone mineral density","volume":"23","author":"Mallon","year":"2010","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/8756-3282(94)00028-X","article-title":"Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study","volume":"16","author":"Serrano","year":"1995","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s002239900288","article-title":"Bone mineral density in patients with human immunodeficiency virus infection","volume":"61","author":"Paton","year":"1997","journal-title":"Calcified Tissue International"},{"issue":"17","key":"10.1016\/j.beem.2010.11.003_bib67","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.003_bib68","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1210\/jc.2007-1660","article-title":"Clinical review #: low body weight mediates the relationship between HIV infection\u00a0and low bone mineral density: a meta-analysis","volume":"92","author":"Bolland","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"13","key":"10.1016\/j.beem.2010.11.003_bib69","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","article-title":"Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy","volume":"17","author":"Bruera","year":"2003","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib70","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bone.2005.11.001","article-title":"Potential predictive factors of osteoporosis in HIV-positive subjects","volume":"38","author":"Fausto","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.beem.2010.11.003_bib72","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","article-title":"Continuous antiretroviral therapy decreases bone mineral density","volume":"23","author":"Grund","year":"2009","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib73","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1210\/jcem.86.8.7728","article-title":"Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting","volume":"86","author":"Huang","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1016\/j.beem.2010.11.003_bib74","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","article-title":"Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir","volume":"15","author":"Nolan","year":"2001","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib75","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","article-title":"Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy","volume":"14","author":"Tebas","year":"2000","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ajcn\/74.5.679","article-title":"Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women","volume":"74","author":"McDermott","year":"2001","journal-title":"The American Journal of Clinical Nutrition"},{"issue":"13","key":"10.1016\/j.beem.2010.11.003_bib77","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/00002030-200109070-00019","article-title":"Reduced bone mineral density in HIV-positive individuals","volume":"15","author":"Moore","year":"2001","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1310\/4X0H-UVMJ-BHYW-CPFB","article-title":"Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients","volume":"4","author":"Fernandez-Rivera","year":"2003","journal-title":"HIV Clinical Trials"},{"issue":"7","key":"10.1016\/j.beem.2010.11.003_bib79","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-007-0524-8","article-title":"Risk factors for decreased bone density and effects of HIV on bone in the elderly","volume":"19","author":"Jones","year":"2008","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.beem.2010.11.003_bib80","article-title":"Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial","author":"Hansen","year":"2010","journal-title":"HIV Medicine"},{"issue":"21","key":"10.1016\/j.beem.2010.11.003_bib81","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"5484","key":"10.1016\/j.beem.2010.11.003_bib82","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.289.5484.1501","article-title":"The osteoblast: a sophisticated fibroblast under central surveillance","volume":"289","author":"Ducy","year":"2000","journal-title":"Science"},{"issue":"5484","key":"10.1016\/j.beem.2010.11.003_bib83","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.beem.2010.11.003_bib84","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2474-9-33","article-title":"Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation","volume":"9","author":"Cotter","year":"2008","journal-title":"BMC Musculoskeletal Disorders"},{"issue":"22","key":"10.1016\/j.beem.2010.11.003_bib85","doi-asserted-by":"crossref","first-page":"19247","DOI":"10.1074\/jbc.C200069200","article-title":"Select HIV protease inhibitors alter bone and fat metabolism ex vivo","volume":"277","author":"Jain","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.beem.2010.11.003_bib86","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2249.2004.02568.x","article-title":"Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis","volume":"137","author":"Fakruddin","year":"2004","journal-title":"Clinical and Experimental Immunology"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1172\/JCI15797","article-title":"The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling","volume":"114","author":"Wang","year":"2004","journal-title":"Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib88","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/aid.2006.22.1131","article-title":"Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors","volume":"22","author":"Pan","year":"2006","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib89","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/01.aids.0000176231.24652.02","article-title":"Association between osteopenia\/osteoporosis and the serum RANKL in HIV-infected patients","volume":"19","author":"Konishi","year":"2005","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/aid.2006.0084","article-title":"HIV protease inhibitors selectively induce gene expression alterations associated with\u00a0reduced calcium deposition in primary human osteoblasts","volume":"23","author":"Malizia","year":"2007","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib91","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/COH.0b013e3281a3c092","article-title":"Osteopenia and osteoporosis in HIV: pathogenesis and treatment","volume":"2","author":"Chew","year":"2007","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"9","key":"10.1016\/j.beem.2010.11.003_bib92","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","article-title":"Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system","volume":"93","author":"Triant","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.11.003_bib93","series-title":"18th IAC, Vienna, July 18\u201323,","article-title":"HCV co-infection is associated with a high risk of osteoporotic fractures among HIV-infected patients","author":"Bedimo","year":"2010"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib95","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","article-title":"Secondary causes of osteoporosis","volume":"77","author":"Fitzpatrick","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib96","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/MD8V-5DLG-EN3T-BRHX","article-title":"Alendronate reduces bone resorption in HIV-associated osteopenia\/osteoporosis","volume":"5","author":"Guaraldi","year":"2004","journal-title":"HIV Clinical Trials"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib97","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","article-title":"Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection","volume":"38","author":"Mondy","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.11.003_bib98","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/QAD.0b013e3282ef961d","article-title":"Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV","volume":"21","author":"McComsey","year":"2007","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib99","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/jc.2006-2216","article-title":"Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial","volume":"92","author":"Bolland","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/aid.2008.0183","article-title":"High frequency of vitamin D deficiency in ambulatory HIV-Positive patients","volume":"25","author":"Rodriguez","year":"2009","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib101","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/QAI.0b013e3181caebaa","article-title":"Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency","volume":"54","author":"Rosenvinge","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib102","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1089\/aid.2008.0058","article-title":"Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy","volume":"24","author":"Van Den Bout-Van Den Beukel","year":"2008","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"12","key":"10.1016\/j.beem.2010.11.003_bib103","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32833c3281","article-title":"Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase","volume":"24","author":"Welz","year":"2010","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib104","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e328337b161","article-title":"High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients","volume":"24","author":"Mueller","year":"2010","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00002030-200303070-00006","article-title":"HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D","volume":"17","author":"Cozzolino","year":"2003","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib106","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1124\/mol.108.053660","article-title":"Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells","volume":"75","author":"Ellfolk","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/j.beem.2010.11.003_bib107","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/14656566.9.7.1197","article-title":"Experience with tenofovir disoproxil fumarate for antiretroviral therapy","volume":"9","author":"Stephan","year":"2008","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib108","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000441-200212000-00011","article-title":"Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity","volume":"324","author":"Coca","year":"2002","journal-title":"The American Journal of the Medical Sciences"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00000441-200306000-00006","article-title":"Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity","volume":"325","author":"Perazella","year":"2003","journal-title":"The American Journal of the Medical Sciences"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"Verhelst","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1016\/j.beem.2010.11.003_bib111","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00002030-200304110-00026","article-title":"Renal lesions in HIV-1-positive patient treated with tenofovir","volume":"17","author":"Creput","year":"2003","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib112","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib113","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.48.5.1469-1487.2004","article-title":"Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques","volume":"48","author":"Van Rompay","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1016\/j.beem.2010.11.003_bib114","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.beem.2010.11.003_bib115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"Post","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"issue":"5","key":"10.1016\/j.beem.2010.11.003_bib116","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1016\/j.beem.2010.11.003_bib117","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.11.003_bib118","series-title":"17th Conference on Retroviruses and Opportunistic infections","article-title":"Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC\/3TC or TDF\/FTC with EFV or ATV\/r for initial treatment of HIV-1 infectio","author":"McComsey","year":"2010"},{"key":"10.1016\/j.beem.2010.11.003_bib119","series-title":"16th Conference on retroviruses and opportunistic infections","article-title":"Simplification with fixed-dose tenofovir\/emtricitabine or abacavir\/lamivudine in adults with suppressed HIV replication; the STEAL study, a randomised, open-label 96 week non-inferiority trial","author":"Cooper","year":"2009"},{"issue":"8","key":"10.1016\/j.beem.2010.11.003_bib120","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/aid.2009.0308","article-title":"Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users","volume":"26","author":"Childs","year":"2010","journal-title":"AIDS Research and Human Retroviruses"},{"issue":"4","key":"10.1016\/j.beem.2010.11.003_bib121","first-page":"1","article-title":"Tenofovir-associated bone density loss","volume":"6","author":"Grigsby","year":"2010","journal-title":"Therapeutics and Clinical Risk Management"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:43:33Z","timestamp":1761497013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X10001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521690X10001739"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2010.11.003","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2010.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}